Browsing NTNU Open by Author "Johannessen, Hans Olaf"
Now showing items 1-2 of 2
-
Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial
von Döbeln, Gabriella Alexandersson; Klevebro, Fredrik; Jacobsen, Anne-Birgitte; Johannessen, Hans Olaf; Nielsen, Niels Hilmer; Johnsen, Gjermund; Hatlevoll, Ingunn; Glenjen, Nils; Friesland, Signe; Lundell, Lars R.; Yu, Jingru; Nilsson, Magnus (Peer reviewed; Journal article, 2019)NeoRes I is a randomized phase II trial comparing neoadjuvant chemoradiotherapy with neoadjuvant chemotherapy in the treatment of resectable cancer of the esophagus or gastroesophageal junction. Patients with biopsy-proven ... -
Oncological outcomes of standard versus prolonged time to surgery after neoadjuvant chemoradiotherapy for oesophageal cancer in the multicentre, randomised, controlled NeoRes II trial
Nilsson, K.; Klevebro, F.; Sunde, B.; Rouvelas, I.; Lindblad, M.; Szabo, E.; Halldestam, I.; Smedh, U.; Wallner, B.; Johansson, J.; Johnsen, Gjermund; Aahlin, Eirik Kjus; Johannessen, Hans Olaf; Alexandersson von Döbeln, von; Hjortland, Geir Olav; Wang, N.; Shang, Y.; Borg, D.; Quaas, A.; Bartella, I.; Bruns, C.; Schröder, W.; Nilsson, M. (Peer reviewed; Journal article, 2023)Background The optimal time to surgery (TTS) after neoadjuvant chemoradiotherapy (nCRT) for oesophageal cancer is unknown and has traditionally been 4-6 weeks in clinical practice. Observational studies have suggested ...